The latest price target for Lexeo Therapeutics (NASDAQ:LXEO) was reported by Chardan Capital on January 13, 2026. The analyst firm set a price target for $17.00 expecting LXEO to rise to within 12 months (a possible 205.21% upside). 25 analyst firms have reported ratings in the last year.

The latest analyst rating for Lexeo Therapeutics (NASDAQ:LXEO) was provided by Chardan Capital, and Lexeo Therapeutics maintained their buy rating.

There is no last upgrade for Lexeo Therapeutics

There is no last downgrade for Lexeo Therapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Lexeo Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Lexeo Therapeutics was filed on January 13, 2026 so you should expect the next rating to be made available sometime around January 13, 2027.

While ratings are subjective and will change, the latest Lexeo Therapeutics (LXEO) rating was a maintained with a price target of $17.00 to $17.00. The current price Lexeo Therapeutics (LXEO) is trading at is $5.57, which is out of the analyst’s predicted range.